LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
Updated Clinical Data in PCNSLIncreased Guidance on Year-End Data in CLLCompany to Host Webcast at 8:30 a.m. ETLEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026;
Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., May 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally
Management to host conference call today at 4:30 p.m. ETLEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD)
LEXINGTON, Mass., Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally
LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced
Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948),
